Review
Oncology
Jane E. Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Allison Trail, Rebecca E. Waters, Jaffer Ajani
Summary: Human epidermal growth factor receptor-2 (HER2) is a well-known cancer target with various therapies available. However, the response and effectiveness of HER2-targeted agents differ among different tumor types, including gastric adenocarcinomas (GACs). GACs exhibit heterogeneity in HER2 expression, both within and between tumors, which poses challenges in assessing the efficacy of HER2-targeted agents. The recent approval of trastuzumab deruxtecan, an antibody drug conjugate, for refractory HER2-positive advanced GAC patients shows promise. Ongoing research aims to understand resistance patterns and intra-tumor heterogeneity to improve treatment outcomes. This review discusses the current status of HER2-targeted therapy in GACs and explores new therapies under investigation.
Article
Medicine, Research & Experimental
Rohit Sharma, Manoj Kumbhakar, Archana Mukherjee
Summary: Human epidermal growth factor receptor 2 (HER2) is overexpressed in various types of cancer, with combination therapy using trastuzumab and pertuzumab antibodies showing improved survival outcomes in breast cancer patients. Radiolabeled and fluorescently labeled antibodies were used in in vitro studies to investigate binding synergism in HER2 overexpressing cell lines. The results showed enhanced uptake of pertuzumab and its F(ab')(2) fragments when combined with trastuzumab, indicating synergism in their binding to HER2.
MOLECULAR PHARMACEUTICS
(2021)
Article
Gastroenterology & Hepatology
Xiyang Wei, Lei Zhao, Ruizhe Ren, Fubo Ji, Shuting Xue, Jianjuan Zhang, Zhaogang Liu, Zhao Ma, Xin W. Wang, Linda Wong, Niya Liu, Jiong Shi, Xing Guo, Stephanie Roessler, Xin Zheng, Junfang Ji
Summary: miR-125b loss activates the HIF1 alpha/pAKT loop, contributing to HCC resistance to TACE. Key nodes in this axis hold the potential in assisting patients with HCC to choose TACE therapy.
Article
Multidisciplinary Sciences
Yi Rao, Zachary Samuels, Lukas M. Carter, Sebastien Monette, Sandeep Surendra Panikar, Patricia M. R. Pereira, Jason S. Lewis
Summary: HER2 is overexpressed in various cancers. Combining trastuzumab with lutetium-177 can deliver radiation to gastric tumors with minimal toxicity. Lovastatin can enhance cell surface HER2 levels and improve the therapeutic efficacy of [177Lu]Lu-DOTA-trastuzumab.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Oncology
Giandomenico Roviello, Giuseppe Aprile, Alberto D'Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini, Martina Catalano
Summary: Gastric cancer is a common malignancy worldwide, with HER2 expression playing a key role in treatment. Resistance to therapy and novel treatment approaches are the current focus of research.
Article
Oncology
Shukui Qin, Jiafu Ji, Rui-Hua Xu, Wei Wang, Yong Tang, Feng Bi, Jin Li, Kang Wang, Jian-Ming Xu, Qingxia Fan, Wuyun Su, Lin Shen
Summary: The study aimed to evaluate the safety and effectiveness of trastuzumab plus chemotherapy in Chinese patients with HER2-positive metastatic gastric cancer. Results showed that trastuzumab treatment improved patients' overall survival and progression-free survival, with a safety profile consistent with previous knowledge.
Article
Oncology
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F. Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The US FDA approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy specifically for HER2-low metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Hung-Pei Tsai, Chien-Ju Lin, Chieh-Hsin Wu, Yi-Ting Chen, Ying-Yi Lu, Aij-Lie Kwan, Ann-Shung Lieu
Summary: This study found that EGFR-positive expression is associated with reduced overall survival in brain astrocytomas, while p53 expression does not show significant correlation with survival. In patients with low p53 expression, EGFR-positive staining is associated with worse survival. The combined expression of EGFR and p53 may have prognostic significance in astrocytomas.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Cell Biology
Xuan Wang, Shuyong Wang, Baolin Guo, Yuxin Su, Zuolong Tan, Mingyang Chang, Jinmei Diao, Yi Zhao, Yunfang Wang
Summary: The study presents a method for establishing and expanding human primary epidermal organoids under a chemically defined condition, which show tolerance to dermatophyte infections caused by Trichophyton Rubrum. This experimental model provides new insights into the pathogenesis of T. rubrum infections and serves as a potential tool for studying and testing antifungal drugs.
CELL DEATH & DISEASE
(2021)
Article
Surgery
Takaaki Arigami, Daisuke Matsushita, Keishi Okubo, Masataka Shimonosono, Ken Sasaki, Yusuke Tsuruda, Yoshiaki Kita, Kan Tanabe, Shinichiro Mori, Shigehiro Yanagita, Yoshikazu Uenosono, Akihiro Nakajo, Hiroshi Kurahara, Takao Ohtsuka
Summary: This study investigated the clinical indications and prognostic significance of surgical interventions after chemotherapy using trastuzumab-containing regimens for HER2-positive advanced gastric cancer patients. They developed a scoring system to predict the prognosis associated with conversion surgery. The study found that age, peritoneal dissemination, histological type were independent prognostic factors, and the patients who underwent conversion surgery had better prognosis. The scoring system based on age, peritoneal dissemination, and histological type was significantly correlated with the presence or absence of conversion surgery and the prognosis of HER2-positive AGC patients.
Review
Oncology
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Summary: This article provides a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, with a focus on recently presented and published clinical trials in this setting.
Article
Medicine, General & Internal
Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu
Summary: This study investigated the short-term clinical efficacy of neoadjuvant therapies trastuzumab and trastuzumab+pertuzumab for early HER2-positive breast cancer patients in China. It was found that patients in the trastuzumab+pertuzumab group had a higher pCR rate with tolerable toxic side effects compared to those in the trastuzumab group.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Pan Liu, Yang Zhang, Weipeng Su, Huarong Zhao
Summary: The study found that over-expression of miR-21 was correlated with the grading and malignancy of glioma, and was positively correlated with the expression of EGFR and VEGF. MiR-21 and grading were identified as independent risk factors for the prognosis of glioma.
ACTA MEDICA MEDITERRANEA
(2021)
Article
Multidisciplinary Sciences
Jianhua Wu, Qun Zhao, Yue Zhao, Xiaoyun Zhang, Yuan Tian, Zhanjun Guo
Summary: The study suggests that Dicer overexpression can induce HER2 overexpression in gastric cancer cells, enhancing the inhibitory effect of trastuzumab. Additionally, calcitriol can also upregulate HER2 expression, increasing sensitivity to trastuzumab.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Masahiko Aoki, Satoru Iwasa, Narikazu Boku
Summary: T-DXd, a novel HER2-targeted antibody-drug conjugate, shows high response rates and significant survival benefits in HER2-positive gastric cancer treatment, and exhibits anti-tumor activity to HER2-negative tumor cells. Its efficacy has been demonstrated in several clinical studies, indicating potential for further progress in treatment of both strongly and weakly HER2 positive gastric cancer.